CELLforCURE by SEQENS, based near Paris, is a leader in the manufacturing of Advanced Therapy Medicinal Products (ATMPs), specialized in both autologous and allogeneic cell and gene therapy solutions. With over a decade of expertise, we provide comprehensive end-to-end services, from Phase I to full-scale commercial production. Our cutting-edge “one-stop-shop” facility spans 10,000 sqm, including 2,200 sqm of GMP-certified production areas and 7 independent manufacturing lines, each equipped with 8 cleanrooms, ensuring maximum safety and compliance for every product. As a trusted comprehensive solution provider, we facilitate seamless project development, leveraging in-house Quality Control for 90% of processes to deliver drug products. With a unique blend of CDMO heritage and proven commercial manufacturing expertise, CELLforCURE is the ideal partner to help bring your innovative therapies to life, transforming groundbreaking ideas into commercial success.
| Website | https://cellandgene.seqens.com/ |
| Revenue | $1.1 billion |
| Employees | 121 (72 on RocketReach) |
| Founded | 2014 |
| Industry | Biotechnology Research |
Looking for a particular CELLforCURE by Seqens employee's phone or email?
The CELLforCURE by Seqens annual revenue was $1.1 billion in 2026.
Marc-Olivier Mignon is the CEO of CELLforCURE by Seqens.
72 people are employed at CELLforCURE by Seqens.